Please assess the completion status of the following clinical trial:

Trial Title: A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All patients must sign an informed consent prior to participation in the trial, which includes medication washout and restrictions.~2. All patients must have a diagnosis of chronic obstructive pulmonary disease according to the GOLD criteria and must meet the following spirometric criteria:~   a post-bronchodilator FEV1 \< 80% of predicted normal, a post-bronchodilator FEV1/FVC \< 70% at Visit 1, and a morning FEV1 \<= 65% predicted at Visit 2.~3. Male or female patients 40 years of age or older.~4. Patients must be current or ex-smokers with a smoking history of more than 10 pack-years.~5. Patients must be able to perform technically acceptable pulmonary function tests.~6. Patients must be able to inhale medication in a competent manner from the HandiHaler® device, the Blue Inhaler device, and from a metered dose inhaler (MDI).~Exclusion Criteria:~1. Patients with significant diseases other than COPD.~2. Patients with a recent history (i.e., six months or less) of myocardial infarction.~3. Patients who have been hospitalized for heart failure (NYHA class III or IV) within the past year.~4. Any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year.~5. Patients with a history of cancer within the last five years.~6. Patients with known narrow-angle glaucoma.~7. Patients with a history of asthma, allergic rhinitis or atopy or who have a total blood eosinophil count \>= 600/mm3.~8. Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.~9. Patients with known active tuberculosis.~10. Patients with significant alcohol or drug abuse within the past two years.~11. Patients who have undergone thoracotomy with pulmonary resection.~12. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the study.~13. Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy.~14. Patients who are being treated with antihistamines (H1 receptor antagonists) for asthma or excluded allergic conditions.~15. Patients who have taken an investigational drug within one month or six half lives prior to Visit 1.~16. Patients who have been treated with oral beta-adrenergics within one month prior to Visit 1.~17. Patients who have been treated with antileukotrienes or leukotriene receptor antagonists for any disease within one month prior to Visit 1.~18. Patients who have been treated with oral steroids within six weeks prior to Visit 1.~19. Patients who have been treated with monoamine oxidase inhibitors or tricyclic antidepressants within one month prior to Visit 1.~20. Patients who have been treated with cromolyn sodium or nedocromil sodium within one month prior to Visit 1.~21. Patients who have been treated with inhaled steroids within two months prior to Visit 1, including combinations of inhaled steroids and long-acting beta-adrenergics.~22. Patients with known hypersensitivity to anticholinergic drugs, beta adrenergics, lactose or any other components of the inhalation capsule delivery system or any other components of the aerosol delivery systems.~23. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for the previous three months.~24. Patients with any respiratory infections in the six weeks prior to the Screening Visit (Visit 1) or during the run-in period.~25. Patients who are currently participating in another study.~26. Patients requiring more than eight puffs of salbutamol on three or more consecutive days during the run-in period.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).